In a process called thrombolysis (the breakdown of a thrombus), fibrinolytic drugs are used. They are given following a heart attack to dissolve the thrombus blocking the coronary artery; experimentally after a stroke to allow blood flow back to the affected part of the brain; and in the event of pulmonary embolism. Thrombolysis refers to the dissolution of the thrombus due to various agents while<unk>  refers specifically to the agents causing fibrin breakdown in the clot. Antifibrinolytics, such as aminocaproic acid (ε-aminocaproic acid) and tranexamic acid are used as inhibitors of<unk> . Their application may be beneficial in patients with hyperfibrinolysis because they arrest bleeding rapidly if the other components of the haemostatic system are not severely affected. This may help to avoid the use of blood products such as fresh frozen plasma with its associated risks of infections or anaphylactic reactions.
Fibrinolysis
Thrombolysis
Argon plasma coagulation
Prothrombin complex concentrate
Thrombectomy
Tissue plasminogen activator
Low-molecular-weight heparin
Tinzaparin sodium